Further research on longer-term effects of maternal prenatal TDF use is important given the majority of HIV-infected women are prescribed a TDF-containing prevention of mother-to-child transmission regimen.
Switching to dolutegravir plus darunavir/ritonavir provided a simple and safe rescue regimen, controlling viral replication in a high proportion of patients.
Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.
Findings show that HIV status was associated with an increased rate of incidental carotid plaque, noncalcified plaque, and high-risk plaque.
Daily cannabis use remained significantly associated with lower odds of steatosis even after adjustment for BMI, which is known to be inversely correlated with cannabis use.
Maraviroc (MVC)-containing HIV PrEP regimens are well tolerated for preventing HIV infection in uninfected women.
Women should not be denied the use of progestin-only injectables because of concerns about the possible increased risk of acquiring HIV.
Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.
Many women who are newly diagnosed with HIV have already been diagnosed but are not getting HIV medical care.
HIV PrEP in the UK for men who have sex with men might be cost-effective.
One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.
Several technological advances have been developed to improve adherence to antiretroviral and preexposure prophylaxis therapy.
Dr Sara Gianella Weibel talks with Anthony B, a patient with HIV and end-stage amyotrophic lateral sclerosis and the first participant enrolled in the "Last Gift" end-of-life study, about his experience as part of this new end-of-life model to study HIV persistence.
Dr Sara Gianella Weibel talks with Dr Davey Smith, head of the Division of Infectious Disease at the University of California, San Diego, about a proposed new model to study HIV persistence, called the Last Gift study.
Dr Sara Gianella talks with Brooke Sullivan, a transgender woman and HIV activist, about ways to improve transgender individuals' involvement in HIV research.
Dr Sara Gianella talks with Dr Sheldon Morris, from the University of California San Diego AntiViral Research Center about an upcoming PrEP study in transgender people, including understanding HIV prevention in this population, uptake of PrEP, and adherence to treatment.
Mother-to-child HIV transmission rates are low in the presence of antiretroviral therapy but increase once ART stops at 6 months postpartum.
Persons living with HIV infection have a higher risk for cardiovascular disease; use of some antiretroviral agents can exacerbate this risk.
Critics of the FDA's current restriction on blood donation from MSM argue that it is unnecessary and discriminatory, and propose a policy based on individual risk rather than sexual orientation.
Drs Gianella and Karris discuss the many factors that play a role in the underrepresentation of women in HIV research.
SIGN UP FOR FREE E-NEWSLETTERS
Infectious Disease Advisor Articles
- Pediatric Outpatient Antimicrobial Stewardship: Minimizing Antibiotic Duration
- Are Antibiotic Stewardship Programs the Antidote to Antibiotic Overuse?
- Better Detection and Treatment Needed for H pylori Infections in Children
- FDA Approves New Hepatitis B Vaccine for Adults
- Strategies for Preventing Antibiotic Resistance in Acne